Morgan Stanley double-upgrades Biogen and says the stock can surge another 30% (BIIB)

**

· *Morgan Stanley on Monday upgraded Biogen from underweight to overweight — a rare double upgrade — citing compelling risk versus reward in the long term.*
· *The firm also boosted its price target on Biogen to $357 from $263. The new target represents a more than 30% upside from where Biogen closed on Friday.*
·...